NASDAQ:DNLI

Denali Therapeutics Stock Forecast, Price & News

$73.03

-0.96 (-1.30 %)

(As of 01/15/2021 08:00 PM ET)

Add

Compare

Today's Range

$69.50

Now: $73.03▼

$74.31

50-Day Range

$60.97

MA: $77.92▼

$93.56

52-Week Range

$12.39

Now: $73.03▼

$93.94

Volume31,178 shs

Average Volume828,510 shs

Market Capitalization$8.76 billion

P/E RatioN/A

Dividend YieldN/A

Beta2

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 that has completed Phase 1b clinical trials and DNL151, which are in Phase 1 and Phase 1b clinical trials for Parkinson's disease. It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small molecule RIPK1 inhibitor product candidate that is in Phase 1b clinical trial for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). In addition, the company develops enzyme transport vehicle: iduronate 2-sulfatase, an enzyme replacement therapy program for MPS II, a lysosomal storage disorder; antibody transport vehicle (ATV): alpha-synuclein (aSyn) program, a protein that spreads throughout the brain in Parkinson's disease; ATV: triggering receptor expressed in myeloid cells 2, a therapeutic candidate designed to rescue microglial function in Alzheimer's disease; and ATV: Tau, a therapeutic targeting the spreading of Tau. Further, it has various seed programs under the research, discovery, and preclinical stages of development. Denali Therapeutics Inc. has collaboration agreement with Takeda Pharmaceutical Company and Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, Centogene, and MedGenome Labs Private Ltd; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

MarketRank^™

Overall MarketRank^™

1.11 out of 5 stars

1.4 Analyst's Opinion

Consensus Rating
Denali Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 9 buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $51.20, Denali Therapeutics has a forecasted downside of 29.9% from its current price of $73.03.
Amount of Analyst Coverage
Denali Therapeutics has only been the subject of 4 research reports in the past 90 days.

2.5 Community Rank

Outperform Votes
Denali Therapeutics has received 396 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Denali Therapeutics has received 398 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Denali Therapeutics has received 50.13% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Denali Therapeutics and other stocks. Vote “Outperform” if you believe DNLI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe DNLI will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Denali Therapeutics does not currently pay a dividend.
Dividend Growth
Denali Therapeutics does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Denali Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $21,901,850.00 in company stock.
Percentage Held by Insiders
Only 19.30% of the stock of Denali Therapeutics is held by insiders.
Percentage Held by Institutions
68.15% of the stock of Denali Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Denali Therapeutics are expected to decrease in the coming year, from ($2.20) to ($2.22) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Denali Therapeutics is -33.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Denali Therapeutics is -33.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Denali Therapeutics has a P/B Ratio of 17.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biological products, except diagnostic

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:DNLI

Previous Symbol

CUSIPN/A

CIK1714899

Webwww.denalitherapeutics.com

Phone650-866-8548

Employees281

Debt

Debt-to-Equity RatioN/A

Current Ratio9.21

Quick Ratio9.21

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$26.68 million

Price / Sales328.25

Cash FlowN/A

Price / Cash FlowN/A

Book Value$4.11 per share

Price / Book17.77

Profitability

EPS (Most Recent Fiscal Year)($2.07)

Net Income$-197,610,000.00

Net Margins-968.59%

Return on Equity-39.19%

Return on Assets-30.71%

Miscellaneous

Outstanding Shares119,918,000

Market Cap$8.76 billion

Next Earnings Date2/25/2021 (Estimated)

OptionableOptionable

$73.03

-0.96 (-1.30 %)

(As of 01/15/2021 08:00 PM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive DNLI News and Ratings via Email

Sign-up to receive the latest news and ratings for DNLI and its competitors with MarketBeat's FREE daily newsletter.

Denali Therapeutics (NASDAQ:DNLI) Frequently Asked Questions

How has Denali Therapeutics' stock price been impacted by Coronavirus?

Denali Therapeutics' stock was trading at $16.88 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, DNLI stock has increased by 332.6% and is now trading at $73.03.
View which stocks have been most impacted by COVID-19.

Is Denali Therapeutics a buy right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Denali Therapeutics in the last twelve months. There are currently 3 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Denali Therapeutics stock.
View analyst ratings for Denali Therapeutics or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Denali Therapeutics?

Wall Street analysts have given Denali Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Denali Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Denali Therapeutics' next earnings date?

Denali Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for Denali Therapeutics.

How were Denali Therapeutics' earnings last quarter?

Denali Therapeutics Inc. (NASDAQ:DNLI) released its quarterly earnings data on Thursday, November, 5th. The company reported ($0.54) earnings per share for the quarter, missing the Zacks' consensus estimate of $4.19 by $4.73. The company had revenue of $9.39 million for the quarter, compared to the consensus estimate of $564.69 million. Denali Therapeutics had a negative return on equity of 39.19% and a negative net margin of 968.59%.
View Denali Therapeutics' earnings history.

What price target have analysts set for DNLI?

12 brokers have issued 12-month price targets for Denali Therapeutics' stock. Their forecasts range from $20.00 to $100.00. On average, they anticipate Denali Therapeutics' stock price to reach $51.20 in the next year. This suggests that the stock has a possible downside of 29.9%.
View analysts' price targets for Denali Therapeutics or view Wall Street analyst' top-rated stocks.

Who are some of Denali Therapeutics' key competitors?

Some companies that are related to Denali Therapeutics include Seagen (SGEN), BioNTech (BNTX), Novozymes A/S (NVZMY), CRISPR Therapeutics (CRSP), argenx (ARGX), Bio-Techne (TECH), QIAGEN (QGEN), Repligen (RGEN), Neurocrine Biosciences (NBIX), Fate Therapeutics (FATE), Adaptive Biotechnologies (ADPT), Twist Bioscience (TWST), Novavax (NVAX), Acceleron Pharma (XLRN) and Iovance Biotherapeutics (IOVA).
View all of DNLI's competitors.

What other stocks do shareholders of Denali Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Denali Therapeutics investors own include Progenics Pharmaceuticals (PGNX), Editas Medicine (EDIT), Intellia Therapeutics (NTLA), Sangamo Therapeutics (SGMO), Kratos Defense & Security Solutions (KTOS), CRISPR Therapeutics (CRSP), Anavex Life Sciences (AVXL), NVIDIA (NVDA), Invitae (NVTA) and Pretium Resources Inc. (PVG.TO) (PVG).

Who are Denali Therapeutics' key executives?

Denali Therapeutics' management team includes the following people:

Dr. Ryan J. Watts Ph.D., Co-Founder, Pres, CEO & Director (Age 44, Pay $887.99k)
Dr. Alexander O. Schuth M.D., Co-Founder, COO & Sec. (Age 47, Pay $611.86k)
Dr. Marc Tessier-Lavigne, Co-Founder, Chairman of Scientific Advisory Board & Independent Director (Age 60, Pay $55k)
Mr. Steve E. Krognes, CFO & Treasurer (Age 52, Pay $665.91k)
Dr. Carole Ho, Chief Medical Officer & Head of Devel. (Age 47, Pay $624.8k)
Mr. Tyler M. Nielsen, VP of Corp. Fin. (Age 42)
Dr. Dana Andersen, Chief Technical and Manufacturing Officer
Mr. Joe Lewcock, Chief Scientific Officer
Dr. Laura Hansen, VP of Investor Relations
Mr. Chris Walsh, Associate Gen. Counsel

When did Denali Therapeutics IPO?

(DNLI) raised $149 million in an initial public offering (IPO) on Friday, December 8th 2017. The company issued 8,300,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs, Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Evercore ISI was co-manager.

What is Denali Therapeutics' stock symbol?

Denali Therapeutics trades on the NASDAQ under the ticker symbol "DNLI."

Who are Denali Therapeutics' major shareholders?

Denali Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Bellecapital International Ltd. (0.01%) and Patriot Financial Group Insurance Agency LLC (0.00%). Company insiders that own Denali Therapeutics stock include Alexander O Schuth, Carole Ho, David P Schenkein, Douglas K Bratton, Marc Tessier-Lavigne, Ryan J Watts and Steve E Krognes.
View institutional ownership trends for Denali Therapeutics.

Which major investors are selling Denali Therapeutics stock?

DNLI stock was sold by a variety of institutional investors in the last quarter, including Bellecapital International Ltd., and Patriot Financial Group Insurance Agency LLC. Company insiders that have sold Denali Therapeutics company stock in the last year include Alexander O Schuth, Carole Ho, David P Schenkein, Douglas K Bratton, Marc Tessier-Lavigne, Ryan J Watts, and Steve E Krognes.
View insider buying and selling activity for Denali Therapeutics or view top insider-selling stocks.

How do I buy shares of Denali Therapeutics?

Shares of DNLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Denali Therapeutics' stock price today?

One share of DNLI stock can currently be purchased for approximately $73.03.

How big of a company is Denali Therapeutics?

Denali Therapeutics has a market capitalization of $8.76 billion and generates $26.68 million in revenue each year. The company earns $-197,610,000.00 in net income (profit) each year or ($2.07) on an earnings per share basis. Denali Therapeutics employs 281 workers across the globe.

What is Denali Therapeutics' official website?

The official website for Denali Therapeutics is www.denalitherapeutics.com.

How can I contact Denali Therapeutics?

Denali Therapeutics' mailing address is 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-866-8548.

This page was last updated on 1/19/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here